Medicinova Inc.'s ibudilast, an experimental anti-inflammatory and neuroprotective agent that has undergone tests in a wide array of neurological conditions, has failed to help addicts kick methamphetamine (MA) dependence in a phase II study, despite early evidence suggesting that it might.